Observational studyArthritis care & research2018
Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.
Observational study in Arthritis care & research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- The 2026 British Society for Rheumatology guideline for the treatment of polymyalgia rheumatica.Rheumatology (Oxford, England) · 2026Guideline
- Comorbidities in polymyalgia rheumatica: a systematic review.Arthritis research & therapy · 2018Pooled it
- Article
- Experience of Australian rheumatologists managing polymyalgia rheumatica: results from a national survey.Internal medicine journal · 2026Article
- Time to remission and steroid doses in older and younger patients with polymyalgia rheumatica.European geriatric medicine · 2026Article
- Physiotherapy for the Management of Polymyalgia Rheumatica: Results From a UK Cross-Sectional Survey.Musculoskeletal care · 2025Article
- Real-world effectiveness and safety of tocilizumab in the management of polymyalgia rheumatica: a retrospective study from the KEIO-PMR cohort.Rheumatology international · 2025Article
- Patterns of pain and stiffness over 5 years in polymyalgia rheumatica: results from the PMR Cohort Study.Rheumatology advances in practice · 2025Article
- Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank.Rheumatology advances in practice · 2023Article
- An update on polymyalgia rheumatica.Journal of internal medicine · 2022Review
- Retrospective Analysis of Factors Associated with Fracture in 714 Patients with Polymyalgia Rheumatica.International journal of rheumatology · 2022Article
- Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study.Rheumatology advances in practice · 2022Article
- Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.Rheumatology and therapy · 2021Article
- Withdrawal of Glucocorticoid Therapy is Difficult in Women with Polymyalgia Rheumatica: An Observational Study.International journal of general medicine · 2021Article
- Fragility fractures and prescriptions of medications for osteoporosis in patients with polymyalgia rheumatica: results from the PMR Cohort Study.Rheumatology advances in practice · 2021Article
- Review
- Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.Current rheumatology reports · 2020Review
- Certain perspectives about the use of corticosteroids for managing hospitalized patients with rheumatic diseases.Clinical rheumatology · 2020Review
- Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.Nature reviews. Rheumatology · 2020Review
- Longitudinal clusters of pain and stiffness in polymyalgia rheumatica: 2-year results from the PMR Cohort Study.Rheumatology (Oxford, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo investigate the use of glucocorticoids (GCs) and related adverse events (AEs) in a long-term, geographically defined cohort of patients with polymyalgia rheumatica (PMR).
methodsUsing a population-based inception cohort, details of GC therapy were abstracted from medical records of all patients diagnosed with PMR in 2000-2014. Age- and sex-matched comparators without PMR were identified from the same underlying population. Cumulative and daily dosage of GC, rate of disease relapse, occurrence of GC-related AEs, and rate of GC discontinuation were analyzed.
resultsThe study included 359 patients with PMR and 359 comparators. The median time to taper below 5 mg/day for 6 months was 1.44 years (95% confidence interval [95% CI] 1.36-1.62), while the median time to permanent discontinuation was 5.95 years (95% CI 3.37-8.88). The mean ± SD cumulative dose of GC at 2 and 5 years was 4.0 ± 3.5 grams and 6.3 ± 9.8 grams, respectively. The mean ± SD daily dose of GC at 2 and 5 years was 6.1 ± 7.6 mg/day and 7.2 ± 9.5 mg/day, respectively. There were no differences in rates of AEs between patients with PMR and comparators for diabetes mellitus, hypertension, hyperlipidemia, or hip, vertebral, or Colles fractures (P > 0.2 for all). Cataracts were more common in patients with PMR than comparators (hazard ratio 1.72 [95% CI 1.23-2.41]).
conclusionRelapse rates in PMR are highest in the early stages of therapy. Despite often protracted therapy, with the exception of cataracts, the rates of studied morbidities linked to GC are not more common in PMR than comparators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.